Gary Scott Leiserowitz, M.D., M.S.
Chair, Department of Obstetrics and Gynecology
Professor, Division of Gynecologic Oncology and Department of Obstetrics and Gynecology
Interim Executive Director, UC Davis Medical Group
To see if Gary Scott Leiserowitz is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).
Department
Locations and Contact
UC Davis Comprehensive Cancer Center
Gynecologic Oncology Clinic
4501 X Street
Sacramento, CA 95817
Phone: 916-734-5959
Lawrence J. Ellison Ambulatory Care Center
Lawrence J. Ellison Ambulatory Care Center
4860 Y St.
Sacramento, CA 95817
Additional Numbers
Clinic Phone
Clinic Fax
Clinic Referral Phone
Philosophy of Care
Gary S. Leiserowitz and his colleagues in the Division of Gynecologic Oncology believe in patient-centered care that is anchored in the most current evidence-based medicine. He works closely with other physicians in medical oncology, radiation oncology and pathology to bring a multidisciplinary focus to each patient’s case. He has been deeply engaged in training the next generation of residents in obstetrics and gynecology and fellows in Gynecologic Oncology to bring cutting edge knowledge and skills to our patients in the region.
Clinical Interests
Dr. Gary S. Leiserowitz is a board-certified specialist in Gynecologic Oncology who provides patient-centered care that is anchored in the most current evidence-based medicine. His extensive surgical experience includes minimally invasive and robotic-assisted procedures for a variety of conditions, as well as open radical procedures for gynecologic cancers. As a member and former director of the Gynecologic Oncology fellowship program at UC Davis, Dr. Leiserowitz is also helping train the next generation of specialists in cancers of the female reproductive system. He has been listed a number of times over the years as one of the “Best Doctors in America,” and Sacramento region's "Top Doctors" including through the current period.
Research/Academic Interests
Dr. Leiserowitz is board-certified in Gynecologic Oncology and specializes in minimally invasive surgery. His research interests includes the development of a potential new blood test for ovarian cancer using glycomics analysis, and outcomes-based research with recent work focusing on identifying predictive factors for long- term survival in ovarian cancer, and currently involved in translational and clinical research projects. He has served as an examiner for the American Board of Obstetrics and Gynecology, both for general exams and sub-specialty exams in Gynecologic Oncology. He was the Fellowship Director of the Gynecologic Oncology fellowship through 2019, as well as the Division Chief, until the successful recruitment of Dr. Rebecca Brooks. He has been Chair of the Department of Obstetrics and Gynecology since 2015. He has been engaged in medical practice leadership for UC Davis Health, serving as Chair of the UC Davis Medical Group until 2022, and is currently the Interim Executive Director.
Division
Gynecologic Oncology
Center/Program Affiliation
UC Davis Comprehensive Cancer Center
Women's Center for Health
UC Davis Medical Group
Undergraduate School
B.S., University of Iowa, Iowa City IA 1976
Medical School
M.D., University of Iowa College of Medicine, Iowa City IA 1981
Other School
M.S., Mayo Graduate School of Medicine, Rochester MN 1993
Internship
Family Medicine, Ventura County Medical Center, Ventura CA 1981-1982
Residency
Obstetrics and Gynecology - Chief Resident, UC Davis Medical Center, Sacramento CA 1986-1989
Residency
Family Medicine, Ventura County Medical Center, Ventura CA 1982-1984
Fellowship
Gynecologic Oncology, Mayo Clinic, Rochester MN 1990-1993
Top Doctors - Sacramento, Sacramento Magazine, 2016, 2017, 2018, 2019, 2020, 2021, 2022
Dean’s Team Award for Excellence - Clinical Care. Interstitial Brachytherapy for Gynecologic Cancers., 2016
Best Doctors in America, 2003, 2005, 2013, 2015
2015 Roy M. Pitkin Award; established in 1998 to honor departments of obstetrics and gynecology that promote and demonstrate excellence in research. The winning article is: Cress RD, Chen YS, Morris CR, Petersen M, Leiserowitz GS. Characteristics of long-term survivors of epithelial ovarian cancer. Obstet Gynecol 2015;126:491-7., 2016
James F. Nolan Award for best clinical paper. 44th Annual WAGO meeting award: “Comparison of LAVH vs. TAH for Endometrial Cancer for Clinical Outcomes and Survival: A Population-Based Study”, 2014
Chen H, Gotimer K, De Souza C, Tepper CG, Karnezis AN, Leiserowitz GS, Chien J, Smith LH. Short-term organoid culture for drug sensitivity testing of high-grade serous carcinoma. Gynecol Oncol. 2020 Jun;157(3):783-792. doi:10.1016/j.ygyno.2020.03.026. Epub 2020 Apr 4. PMID:32253045.
Girda E, Huang EC, Leiserowitz GS, Smith LH. The Use of Endometrial Cancer Patient-Derived Organoid Culture for Drug Sensitivity Testing Is Feasible. Int J Gynecol Cancer. 2017 Oct;27(8):1701-1707. doi:10.1097/IGC.0000000000001061. PMID:28683005.
Carney RP, Hazari S, Colquhoun M, Tran D, Hwang B, Mulligan MS, Bryers JD, Girda E, Leiserowitz GS, Smith ZJ, Lam KS. Multispectral Optical Tweezers for Biochemical Fingerprinting of CD9-Positive Exosome Subpopulations. Anal Chem. 2017 May 16;89(10):5357-5363. doi:10.1021/acs.analchem.7b00017. Epub 2017 Apr 25. PMID:28345878.
Leiserowitz GS, Lin JF, Tergas AI, Cliby WA, Bristow RE. Factors Predicting Use of Neoadjuvant Chemotherapy Compared With Primary Debulking Surgery in Advanced Stage Ovarian Cancer-A National Cancer Database Study. Int J Gynecol Cancer. 2017 May;27(4):675-683. doi:10.1097/IGC.0000000000000967. PMID:28328580.
Cress RD, Chen YS, Morris CR, Petersen M, Leiserowitz GS. Characteristics of Long-Term Survivors of Epithelial Ovarian Cancer. Obstet Gynecol. 2015 Sep;126(3):491-497. doi:10.1097/AOG.0000000000000981. PMID:26244529.
Kim K, Ruhaak LR, Nguyen UT, Taylor SL, Dimapasoc L, Williams C, Stroble C, Ozcan S, Miyamoto S, Lebrilla CB, Leiserowitz GS. Evaluation of glycomic profiling as a diagnostic biomarker for epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2014 Apr;23(4):611-21. doi:10.1158/1055-9965.EPI-13-1073. Epub 2014 Feb 20. PMID:24557531.
Ruhaak LR, Taylor SL, Miyamoto S, Kelly K, Leiserowitz GS, Gandara D, Lebrilla CB, Kim K. Chip-based nLC-TOF-MS is a highly stable technology for large-scale high-throughput analyses. Anal Bioanal Chem. 2013 May;405(14):4953-8. doi:10.1007/s00216-013-6908-z. Epub 2013 Mar 23. PMID:23525540.
Hua S, Williams CC, Dimapasoc LM, Ro GS, Ozcan S, Miyamoto S, Lebrilla CB, An HJ, Leiserowitz GS. Isomer-specific chromatographic profiling yields highly sensitive and specific potential N-glycan biomarkers for epithelial ovarian cancer. J Chromatogr A. 2013 Mar 1;1279:58-67. doi:10.1016/j.chroma.2012.12.079. Epub 2013 Jan 11. PMID:23380366.
Cress RD, Bauer K, O'Malley CD, Kahn AR, Schymura MJ, Wike JM, Stewart SL, Leiserowitz GS. Surgical staging of early stage epithelial ovarian cancer: results from the CDC-NPCR ovarian patterns of care study. Gynecol Oncol. 2011 Apr;121(1):94-9. doi:10.1016/j.ygyno.2010.12.359. Epub 2011 Jan 21. PMID:21256581.